Northwest Competitors

OTC Stocks . USA . 
Stock . Northwest Biotherapeutics
NWBO Stock  USD 0.27  0.01  3.85%   
Northwest Biotherapeutics competes with Celldex Therapeutics, CEL SCI, Morningstar Unconstrained, Thrivent High, and Via Renewables; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Northwest Biotherapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Northwest Biotherapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Northwest Biotherapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Northwest Biotherapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.274.45
Details
Intrinsic
Valuation
LowRealHigh
0.010.244.42
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Northwest Biotherapeutics. Your research has to be compared to or analyzed against Northwest Biotherapeutics' peers to derive any actionable benefits. When done correctly, Northwest Biotherapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Northwest Biotherapeutics.

Northwest Biotherapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Northwest Biotherapeutics and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Northwest and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Northwest Biotherapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RRTLX
+ 0.88
MSTSX
OSHDF
+ 0.86
VIASP
MSTSX
+ 0.79
AQUI
RRTLX
+ 0.76
LBHIX
CVM
+ 0.75
CLDX
70082LAB3
+ 0.72
VIASP
  
High negative correlations   
70082LAB3
- 0.89
CVM
VIASP
- 0.77
CVM
70082LAB3
- 0.75
CLDX
OSHDF
- 0.74
MSTSX
VIASP
- 0.6
CLDX
OSHDF
- 0.57
RRTLX

Risk-Adjusted Indicators

There is a big difference between Northwest OTC Stock performing well and Northwest Biotherapeutics OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Northwest Biotherapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CLDX  2.64 (0.66) 0.00 (2.03) 0.00 
 0.00 
 5.53 
(6.76)
 17.16 
CVM  4.45 (0.38) 0.00  0.51  0.00 
 0.00 
 16.07 
(10.00)
 46.42 
AQUI  2.79 (1.43) 0.00 (11.74) 0.00 
 0.00 
 0.00 
 0.00 
 93.33 
MSTSX  0.55 (0.13) 0.00 (0.85) 0.00 
 0.00 
 1.03 
(1.02)
 7.08 
LBHIX  0.11 (0.02) 0.00 (1.10) 0.00 
 0.00 
 0.24 
(0.24)
 0.94 
VIASP  0.76  0.15  0.08 (0.97) 1.03 
(0.87)
 2.00 
(1.20)
 4.90 
RRTLX  0.28 (0.07) 0.00  4.18  0.00 
 0.00 
 0.40 
(0.56)
 3.47 
OSHDF  46.68  24.81  0.00 (1.39) 0.00 
 0.00 
 0.00 
 0.00 
 1,329 
70082LAB3  0.67  0.10  0.06  0.80  0.81 
(0.84)
 1.78 
(0.78)
 6.86 
SITKF  5.15  0.40  0.05  1.39  4.92 
(8.51)
 14.29 
(9.09)
 30.02 
All Fundamental Data

Northwest Biotherapeutics Competitive Analysis

The better you understand Northwest Biotherapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Northwest Biotherapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Northwest Biotherapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NWBO CLDX CVM AQUI MSTSX LBHIX VIASP RRTLX OSHDF 70082LAB3
 3.85 
 0.27 
Northwest
 1.01 
 25.39 
Celldex
 14.29 
 0.60 
CEL
 93.33 
 0.0004 
Aquagold
 0.65 
 10.76 
Morningstar
 0.24 
 4.21 
Thrivent
 0.17 
 23.58 
Via
 0.50 
 12.10 
RRTLX
 260.00 
 0.04 
Oshidori
 2.51 
 90.00 
70082LAB3
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Dangerous
Out of control
Very steady
Very steady
Very steady
Very steady
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Strong
Very Weak
Good
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Above Average
About Average
Very High
Average
Low
Low
Below Average
Low
Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Sell
Strong Hold
Strong Sell
Hold
Current Ratio
0.1
12.29
7.71
N/A
N/A
N/A
3.49
N/A
N/A
N/A
Net Asset
40.16 M
465.63 M
30.53 M
3.19 K
116.1 M
674.44 M
355.28 M
1.46 B
6.31 B
N/A
EBITDA
184.72 M
(139.03 M)
(27.56 M)
(727.69 K)
N/A
N/A
33.09 M
N/A
(3.49 B)
N/A
Operating Margin
-54.95
-16.34
N/A
N/A
N/A
N/A
-0.14
N/A
1.04
N/A
Five Year Return
N/A
N/A
N/A
N/A
7.5
2.89
8.97
0.0406
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
12.69
6.96
N/A
0.067
N/A
N/A
Beta
-0.0115
1.59
0.69
7.05
N/A
N/A
1.16
N/A
0.67
N/A
Number Of Employees
19
160
N/A
7
1
1
169
1
31
N/A
Three Year Return
N/A
N/A
N/A
N/A
6.47
2.41
N/A
0.0491
N/A
N/A
Cash Flow From Operations
(38.3 M)
(107.29 M)
(22.85 M)
(218.19 K)
N/A
N/A
12.7 M
N/A
499.26 M
N/A
Total Debt
25.16 M
2.54 M
13.57 M
N/A
N/A
N/A
135 M
N/A
N/A
N/A
Bond Positions Weight
N/A
N/A
N/A
N/A
22.72
92.23
N/A
14.43
N/A
N/A
Holdings Turnover
N/A
N/A
N/A
N/A
269.0
N/A
N/A
N/A
N/A
N/A
Return On Asset
-1.26
-0.2
-0.61
-5.5
N/A
N/A
-0.11
N/A
-0.46
N/A
Current Liabilities
64.93 M
30.24 M
4.01 M
794 K
N/A
N/A
N/A
N/A
N/A
N/A
Debt To Equity
-16.14
0.011
0.41
N/A
N/A
N/A
0.69
N/A
N/A
N/A
Short Ratio
13.54
6.61
18.05
N/A
N/A
N/A
0.7
N/A
N/A
N/A
Shares Owned By Institutions
0.23
100.0
10.46
N/A
N/A
N/A
N/A
N/A
0.84
N/A
Market Capitalization
705.3 M
1.7 B
44.71 M
96.58 K
50.36 M
N/A
N/A
N/A
233.49 M
N/A
Price To Earning
58.17
-2.21
-1.14
-0.22
N/A
35.48
26.83
18.25
N/A
N/A
Price To Sales
858.96
170.58
11797.42
N/A
N/A
1.23
N/A
1.57
N/A
N/A
Net Income
179.13 M
(141.43 M)
(32.19 M)
(627.79 K)
N/A
N/A
5.2 M
N/A
(3.15 B)
N/A
Shares Owned By Insiders
10.04
N/A
2.91
N/A
N/A
N/A
N/A
N/A
30.28
N/A
Revenue
1 M
6.88 M
N/A
N/A
N/A
N/A
393.49 M
N/A
(3.1 B)
N/A
Year To Date Return
N/A
N/A
N/A
N/A
10.42
6.59
N/A
-0.0211
N/A
N/A
Working Capital
(40.83 M)
400.57 M
1.33 M
(794 K)
N/A
N/A
N/A
N/A
N/A
N/A
Profit Margin
52.11
N/A
N/A
N/A
N/A
N/A
0.0094
N/A
N/A
N/A
Current Valuation
1.03 B
914.32 M
56.41 M
912.76 K
N/A
N/A
535.95 M
N/A
103.84 M
N/A
Price To Book
N/A
2.12
5.27
N/A
N/A
1.58
N/A
2.13
0.005
N/A
Retained Earnings
(862.01 M)
(1.4 B)
(487.09 M)
(4.18 M)
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
24.1 M
294.94 M
5.89 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Position Weight
N/A
N/A
N/A
N/A
14.28
6.56
N/A
7.22
N/A
N/A
Equity Positions Weight
N/A
N/A
N/A
N/A
61.63
0.07
N/A
38.52
N/A
N/A
Shares Outstanding
1.05 B
66.34 M
63.81 M
965.83 K
N/A
N/A
N/A
N/A
6.11 B
N/A
Annual Yield
N/A
N/A
N/A
N/A
0.0204
0.0612
0.0972
0.0206
N/A
N/A
Return On Equity
N/A
-0.3
-2.5
N/A
N/A
N/A
0.017
N/A
-0.5
N/A
Z Score
-0.6
N/A
N/A
N/A
N/A
N/A
1.0
N/A
N/A
N/A
Number Of Shares Shorted
14.14 M
7.31 M
4.43 M
N/A
N/A
N/A
4.29 K
N/A
N/A
N/A
Book Value Per Share
-0.1
11.85
0.16
-1.18
N/A
N/A
3.66
N/A
0.89
N/A
Minimum Initial Investment
N/A
N/A
N/A
N/A
N/A
2 K
N/A
N/A
N/A
N/A
Total Asset
40.16 M
465.63 M
30.53 M
3.19 K
215.11 M
347.66 M
355.28 M
1.03 B
6.31 B
N/A
Target Price
5.0
67.1
7.73
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
0.02
0.73
0.14
N/A
N/A
Earnings Per Share
-0.063
-2.58
-0.52
-0.63
N/A
N/A
1.17
N/A
N/A
N/A
Ten Year Return
N/A
N/A
N/A
N/A
N/A
6.0
N/A
5.76
N/A
N/A
Cash And Equivalents
9.43 M
356.82 M
22.67 M
1.15 K
N/A
N/A
51.31 M
N/A
N/A
N/A
Cash Per Share
0.01
7.63
0.65
N/A
N/A
N/A
3.23
N/A
N/A
N/A
Gross Profit
1 M
(79.9 M)
(25.36 M)
(143.88 K)
N/A
N/A
74.67 M
N/A
(4.09 B)
N/A
Day Typical Price
0.27
25.34
0.64
4.0E-4
10.76
4.21
23.57
12.1
0.036
90.0
Accumulation Distribution
134101.0
29461.19
245009.0
N/A
N/A
N/A
22.8
N/A
N/A
N/A
Daily Balance Of Power
0.5
(0.25)
(0.77)
(9,223,372,036,855)
(9,223,372,036,855)
(9,223,372,036,855)
(0.40)
9.2 T
9.2 T
9.2 T
Period Momentum Indicator
0.01
(0.26)
(0.10)
(0.01)
(0.07)
(0.01)
(0.04)
0.06
0.026
2.2
Rate Of Daily Change
1.04
0.99
0.86
0.0667
0.99
1.0
1.0
1.0
3.6
1.03
Day Median Price
0.27
25.32
0.66
4.0E-4
10.76
4.21
23.56
12.1
0.036
90.0
Price Action Indicator
0.005
(0.06)
(0.10)
(0)
(0.04)
(0.01)
N/A
0.03
0.013
1.1
Coefficient Of Variation
(1,536)
(565.60)
(1,797)
(812.40)
(816.55)
(1,627)
732.47
(789.16)
690.32
1008.67
Mean Deviation
2.98
2.64
4.45
2.79
0.5477
0.1097
0.7638
0.2815
46.68
0.6677
Jensen Alpha
(0.34)
(0.66)
(0.38)
(1.43)
(0.13)
(0.02)
0.1543
(0.07)
24.81
0.0957
Total Risk Alpha
(0.50)
(0.85)
(0.80)
(2.05)
(0.17)
(0.03)
0.0847
(0.1)
15.0
0.04
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
0.0801
N/A
N/A
0.0582
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
1.7
N/A
N/A
0.9871
Standard Deviation
4.11
3.63
7.2
11.49
0.9321
0.1726
1.16
0.4751
166.15
1.12
Kurtosis
2.85
1.27
5.36
66.0
16.42
0.9557
5.69
19.93
61.03
10.74
Potential Upside
6.67
5.53
16.07
N/A
1.03
0.2364
2.0
0.3971
N/A
1.78
Treynor Ratio
(0.20)
(2.03)
0.5113
(11.74)
(0.85)
(1.10)
(0.97)
4.18
(1.39)
0.8013
Maximum Drawdown
22.79
17.16
46.42
93.33
7.08
0.9445
4.9
3.47
1328.57
6.86
Variance
16.9
13.14
51.81
131.99
0.8687
0.0298
1.33
0.2257
27607.17
1.26
Market Risk Adjusted Performance
(0.19)
(2.02)
0.5213
(11.73)
(0.84)
(1.09)
(0.96)
4.19
(1.38)
0.8113
Risk Adjusted Performance
(0.04)
(0.13)
(0.04)
(0.09)
(0.1)
(0.08)
0.1115
(0.11)
0.125
0.0816
Skewness
1.2
(0.28)
1.66
(8.12)
(3.01)
(0.17)
(1.08)
(3.67)
7.72
0.2779
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
1.03
N/A
N/A
0.811
Information Ratio
(0.08)
(0.19)
(0.06)
(0.13)
(0.18)
(0.37)
0.0904
(0.24)
0.1445
0.0516
Value At Risk
(6.67)
(6.76)
(10.00)
N/A
(1.02)
(0.24)
(1.20)
(0.56)
N/A
(0.78)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
(0.87)
N/A
N/A
(0.84)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
1.3
N/A
N/A
0.9935
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
1.05
N/A
N/A
0.6577

Northwest Biotherapeutics Competition Performance Charts

Five steps to successful analysis of Northwest Biotherapeutics Competition

Northwest Biotherapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Northwest Biotherapeutics in relation to its competition. Northwest Biotherapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Northwest Biotherapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Northwest Biotherapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Northwest Biotherapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Northwest Biotherapeutics position

In addition to having Northwest Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long/short ETFs Thematic Idea Now

Long/short ETFs
Long/short ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Long/short ETFs theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long/short ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Northwest OTC Stock

Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY